NasdaqGS:IDYABiotechs
A Look At IDEAYA Biosciences (IDYA) Valuation After UBS Highlight And Returned GSK Programs
What sparked fresh interest in IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has come into focus after UBS highlighted its clinical pipeline. The firm pointed in particular to darovasertib and the DLL3 antibody drug conjugate, and also noted GlaxoSmithKline returning the Werner Helicase and Pol Theta programs.
See our latest analysis for IDEAYA Biosciences.
Those UBS comments and the upcoming J.P. Morgan Healthcare Conference are landing at a time when IDEAYA’s share price has already seen a...